RTTNews | Oct 13, 2020 06:16AM EDT

06:16 Tuesday, October 13, 2020 (RTTNews.com) - Medigen Vaccine Biologics Corp. and Dynavax Technologies Corp. (DVAX) announced that MVC has obtained a Taiwan government subsidy for successfully initiating a phase 1 clinical trial in Taiwan. The grant was earmarked by the government for purposes of research and development of a locally produced COVID-19 vaccine. The subsidy will be released at agreed upon milestones in the total amount of up to $16.4 million.

The first participant in phase 1 clinical trial was dosed with MVC's COVID-19 vaccine combined with Dynavax's CpG 1018 adjuvant in early October.

Read the original article on RTTNews ( https://www.rttnews.com/3135708/dynavax-mvc-begins-phase-1-trial-for-adjuvanted-vaccine-candidate-to-prevent-covid-19.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2020 RTTNews.com All Rights Reserved